Clinical Implications Of Apc-Resistance And Factor 5 Leiden Mutational Testing Over A Five Year Period At Yale-New Haven Hospital by Baraban, Ezra
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
January 2016
Clinical Implications Of Apc-Resistance And
Factor 5 Leiden Mutational Testing Over A Five
Year Period At Yale-New Haven Hospital
Ezra Baraban
Yale University
Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Baraban, Ezra, "Clinical Implications Of Apc-Resistance And Factor 5 Leiden Mutational Testing Over A Five Year Period At Yale-New
Haven Hospital" (2016). Yale Medicine Thesis Digital Library. 2037.
https://elischolar.library.yale.edu/ymtdl/2037
 1  
 
 
 
 
 
 
 
 
 
Discordance between Functional Screening and Genetic Confirmatory Diagnostic Tests:  
Five over Five  
Or, 
Clinical Implications of APC-Resistance and Factor 5 Leiden Mutational Testing over a Five 
Year Period at Yale-New Haven Hospital  
 
 
 
 
 
 
Ezra Baraban 
January 8, 2016 
Yale School of Medicine / Department of Lab Medicine 
Mentors: Dr. Christopher Tormey and Dr. Alexa Siddon    
 2  
 
ABSTRACT 
 
               Activated protein C (APC) resistance can be used as a screening test for patients with 
Factor 5 Leiden mutations. We evaluated 2104 patients tested for APC resistance and 4082 
patients for factor 5 Leiden mutations between 2010 and 2015. Greater than 90% of all factor 5 
Leiden mutation tests were negative, representing a potential annual savings of over $40,000. It 
was also noted that quantitative APC resistance values are directly related to the factor 5 Leiden 
genotype. Patients with non-Leiden APC resistance had significantly higher values for APC 
resistance (1.85 vs. 1.97 with p < 0.005). Discordance between APC resistance testing and factor 
5 Leiden testing was also examined, and autoimmune disease and liver transplantation emerged 
as common associations. Based on these observations, we propose specific modifications to the 
thrombophilia diagnostic algorithm that we believe will decrease cost and increase diagnostic 
clarity. 
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INTRODUCTION 
  
               Patients with coagulation disorders are at risk for a variety of complications ranging 
from thrombosis to hemorrhage.  Reliable laboratory testing is required to pinpoint the 
pathophysiologic defect underlying the patient's clinical syndrome.   Some unfortunate 
individuals are born with a genetic tendency toward thrombosis, whereas others acquire risk 
factors over the course of a lifetime.  The most common inherited risk factor for thrombosis is 
the factor 5 Leiden mutation, which is transmitted in an autosomal dominant fashion.  Notably, 
5.2% of white Americans carry a copy of the factor 5 Leiden mutation.  Such carriers of the 
mutation have been estimated to have somewhere between a 10-40% risk of experiencing 
pathological thromboembolism during their lifetime.
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   Such patients are often treated with 
lifelong anticoagulation, a fate laden with potential for unintended but common consequences of 
the concomitant bleeding diathesis. 
 
         The activated form of factor 5, also known as factor 5a, is normally inactivated by activated 
protein C, which proteolytically cleaves factor 5a at three distinct arginine residues, located at 
positions 306, 506, and 679.
2
  The factor 5 Leiden mutation causes production of a mutant factor 
5 protein impervious to regulatory cleavage by activated protein C, a gamma-carboxylated 
endogenous anticoagulant protein also produced by the liver.  The culprit mutation is a G->A 
transition mutation at position 1691 in the factor 5 gene, which results in a substitution of 
glutamine rather than arginine at the 506
th
 amino acid.  Thus, the factor 5 Leiden protein is 
resistant to activated protein C (APC).    
                                                 
1
 Kujovich, JL.  Factor V Leiden Thrombophilia.  Genetics in Medicine 2011.  1-16.   
2
  Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic 
disorders. Blood 2008;112:19–27.  
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        Other, rarer mutations in the factor five gene have been shown to cause APC resistance by 
similar mechanisms.  For example, a G to C mutation which alters arginine 306 to threonine, also 
attenuates APC cleavage of factor 5a, and has been dubbed as the Factor 5 Cambridge mutation. 
3
 A mutation at precisely the same codon that converts arginine 306 to glycine has also been 
reported, and is referred to as the Factor 5 Hong Kong mutation.  
4
 
 
          The clinical evaluation of patients for the factor 5 Leiden mutation is typically a two-step 
process, beginning with a highly sensitive, rapid and inexpensive test for APC resistance.  The 
patients baseline activated partial thromboplastin time is assayed by standard lab techniques, and 
a separate aliquot of the patient’s plasma is treated with activated protein C.  In patients with a 
normal factor 5 gene, the addition of APC will result in cleavage of factors five and eight, 
leading to prolongation of the patients PTT, much the same as in a patient who had congenital 
deficiency of factor five (parahemophilia) or factor eight (hemophilia A).  Hence the ratio of the 
patients PTT following APC administration divided by the baseline PTT is computed as an in 
vitro physiologic index for the extent to which APC is capable of cleaving factors 5 and 8.  The 
higher the ratio, the more APC was able to prolong the PTT by cleaving factors five and 8.  
Patients possessing the factor 5 Leiden mutation synthesize a protein that is relatively impervious 
to cleavage by APC.  The PTT(APC) / PTT ratio in such patients is abnormally low, with the 
clinical cutoff at Yale New Haven Hospital being 2.20.  Thus patients with such a ratio below 
2.20 are deemed to demonstrate APC resistance.   
                                                 
3
 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation 
(Arg306–>Thr) associated with resistance to activated protein C. Blood 1998;91:1140–1144. 
4
 Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong 
Kong Chinese. Blood 1998;91:1135–1139. 
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          Naturally, this screening test should be followed by more specific, precise, and costly 
confirmatory genetic testing for the factor five Leiden gene mutation, which is conducted by 
PCR amplification of the factor five gene, followed by hybridization of an oligonucleotide probe 
with higher affinity for DNA containing the factor five Leiden mutation.  If the Leiden mutation 
is present, the probe will adhere to the amplified DNA, leading to a measurable increase in the 
melting point of the resulting duplex piece of DNA.  It is important to emphasize that the APC 
resistance assay will theoretically detect all the above described mutations in the factor 5 gene 
(Leiden, Hong Kong, Cambridge), as well as other acquired causes of APC resistance mentioned 
below.  However, clearly, the molecular test for the factor five Leiden mutation will only detect 
the factor 5 Leiden mutation, and will certainly fail to detect factor 5 Cambridge, Hong Kong 
mutations, as well as the acquired causes for APC resistance. 
 
          It is currently unknown the current rate at which patients screened for APC resistance at 
our facility are ultimately confirmed to have the factor five Leiden mutation; there are rare 
reports in the literature from populations that are very different than that served by Yale-New 
Haven Hospital.  Further, there are several notable causes of APC resistance that are not due to 
the factor five Leiden mutation.  This list includes elevated factor 8 levels, which can occur in 
pregnancy, chronic inflammatory diseases, increased estrogen exposure, or the presence of 
antiphospholipid antibodies, including those targeting beta-2 glycoprotein 1, cardiolipin, and the 
lupus anticoagulant.   It is also unknown the rate at which such ‘pseudo’ APC resistance occurs.  
Further, it is currently unknown how often clinicians evaluating hypercoagulable patients use the 
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sequential diagnostic scheme described above or directly order the less physiologic but more 
specific, expensive genetic test for factor five Leiden. 
 
          We hypothesize that patients who demonstrate discordance between APC resistance and 
factor five Leiden mutation testing represent a group of patients that are frequently inadequately 
diagnosed and either undertreated or overtreated as a result.  We hypothesize that systematic 
examination of all patients tested for APC resistance and the factor five Leiden mutation over the 
past 5 years at Yale New Haven Hospital will reveal many patients with APC resistance but no 
factor five Leiden mutation.  We believe a significant percentage of these patients may have a 
clinical history of liver transplantation, leading to confounding of their hypercoagulability 
testing.  As chimeras, their liver graft produces the factor five Leiden protein, which is not 
detected with current testing for factor 5 Leiden which analyzes the DNA from peripheral 
leukocytes, not  the patient’s liver cells.  If they’ve experienced a thrombotic event, these 
patients should theoretically receive lifelong anticoagulation despite negative lab testing for the 
factor five Leiden mutation.  Conversely, we hypothesize that the ostensibly paradoxical finding 
of negative APC-resistance testing along with a factor 5 Leiden mutation represents a cohort of 
patients who have undergone allogeneic bone marrow stem cell transplantation.  Their graft, 
from a donor carrying the factor five Leiden mutation, causes the patient’s peripheral leukocytes 
to carry the mutation, which causes positive factor five Leiden mutation testing – which is 
clinically inconsequential because the patient’s liver is producing wild type factor five protein.  
Thus, we aim to perform a comprehensive analysis of APC resistance and factor 5 Leiden 
genetic testing done at Yale New Haven Hospital over the past 5 years.  Specifically, we aim to 
answer the following questions. 
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1] How many patients were tested for APC resistance and for the factor five Leiden 
mutation over the past 5 years at YNHH?  What percentage of APC resistance and factor 
five Leiden mutation tests were positive and negative? 
 
This will enable statistical analysis of hypercoagulability testing, which has implications 
for how to best optimize testing from diagnostic and financial standpoints. 
 
2] What percentage of patients with positive APC resistance were subsequently tested for 
factor 5 Leiden?  Of these patients, what percentage were ultimate positive and negative 
for the factor 5 Leiden mutation? 
 
This will assess the current clinical workflow for following up APC resistance with the 
appropriate diagnostic test 
 
3] How many patients were tested for factor five Leiden mutations but not APC 
resistance?  How many of these patients were negative for factor five Leiden? 
 
This subgroup would be ideal for conducting further diagnostic testing for other factor 
five mutations that are currently missed because clinicians fail to pursue further 
diagnostic workup.  We also hypothesize that if factor 5 Leiden testing was negative, 
patients should be still tested for APC-Resistance, and if positive, should be tested for 
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other more rare factor five mutations (Cambridge or Hong-Kong mutations), depending 
on their clinical history. 
 
4] Of the patients who tested positive for APC-resistance but negative for factor 5 
Leiden, what are the most likely clinical risk factors for acquired APC resistance?   
 
Again, these patients with discordance between APC and factor 5 Leiden testing are ideal 
candidates for more advanced testing for rarer factor 5 mutations, or may be transplant 
recipients with a mutant graft but wild type germline factor five. 
 
5] Is the quantitative value for APC-resistance predictive of the ultimate coagulation 
defect?  What are the average levels of APC resistance of factor 5 Leiden homozygotes, 
heterozygotes, and those who lack the factor 5 Leiden mutation? 
 
This could also enable clinicians to select the proper testing depending on the clinical 
scenario. 
 
6] How many patients tested positive for factor 5 Leiden but negative for APC-
resistance? Are we missing patients with factor 5 Leiden by relying on APC-resistance as 
a screening test?  Are there environmental factors like anticoagulation that are concealing 
APC-resistance and interfering with the diagnostic process for factor 5 Leiden? 
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This will inform us of the actual clinical sensitivity of APC resistance as a 
screening test for factor 5 Leiden.  This will help us produce evidence based 
recommendations for when patients should be tested directly for factor 5 Leiden, rather 
than relying on the traditional sequence of APC-resistance followed by factor 5 Leiden 
testing. 
 
7] Of patients who were tested for factor 5 Leiden but not APC-resistance, what 
percentage were positive and negative for factor 5 Leiden? 
 
This is a very important healthcare utilization question.  If factor 5 Leiden testing is being 
ordered excessively in clinical scenarios where the pre-test probability is low, (ie the 
patients were not tested or tested negative for APC-resistance) many of these patients will 
test negative.  This information could be used to guide provider decision-making about 
hypercoagulability diagnostics. 
 
 
METHODS 
 
Retrospective Analysis of Patient Diagnostic Data 
 
Factor 5 Leiden and APC resistance data from the past 5 years were queried and 
collected using the SoftLabMic program in the department of Lab Medicine at Yale. 
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Data regarding clinical history and specific diagnostic testing were collected using EPIC 
EMR system, and analyzed statistically using Microsoft Excel. 
Patient samples that are deemed appropriate may be sent for clinical testing for the factor 
5 Leiden mutation of other less common mutations in the factor five gene. 
 
Factor 5 Leiden mutation Testing 
 
DNA was isolated from the patient samples and tested for the Factor V Leiden 
mutation.  Regions of the Factor V gene and for wild type Factor V were amplified 
enzymatically, then characterized as positive or negative for the Factor V Leiden 
mutation on agarose gels. The Factor V primers FVNOR and FVMUT (Thromb Haemost 
75:520,1996) and FVFOR2 (Thromb Haemost 74:874,1995) were used. Beta-actin 
primer were used to test integrity of the sample DNA. Positive controls were detected and 
negative controls appropriate. Control PCR indicated the DNA preparation was adequate. 
 
LIMITATIONS 
 
As with any clinical study, confidence in our results can be limited by the size of 
the study.  We aim to study as many patient samples as needed to achieve statistical 
significance as well as confidence that our results will apply to future patients.  As such, 
after conducting initial analysis of patients from the past five years, it is possible that 
more samples from previous years will need to be integrated and analyzed to strengthen 
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our measures of association.  It is also possible to integrate new results from the clinical 
lab as they occur in real time to the study. 
 
Another potential limitation of our study is its external validity or generalizability.  
Since we will be studying patient samples from Yale New Haven Hospital, naturally our 
results will be most applicable to lab practice here.  Since not all laboratories serve the 
same ethnically diverse population, use the same reagents for APC-R and factor 5L 
testing, or clinical diagnostic algorithms, it is possible that even if our results our 
internally valid, they simply may not be applicable to coagulation testing elsewhere.  
Regardless, the opportunity to potentially improve the laboratory practice at YNHH alone 
is more than sufficient justification to study this common but unexplained phenomenon. 
 
RESULTS 
1] 
Between January of 2010 and September of 2015, 2104 patients were tested for 
APC resistance at the Yale New Haven Hospital coagulation laboratory.  Of these, 8.9% 
of them demonstrated APC resistance.  In other words, 188 patients demonstrated APC 
resistance during this time period (table 1).  
 
Over the same time period, in the molecular laboratory of Yale New Haven 
Hospital, 4082 patients were tested for the factor 5 Leiden gene mutation, and 381 or 
9.3% of these patients had a positive test, demonstrating either one or two copies of the 
factor 5 Leiden mutation.  Of these, 379 patients or 99.5% were heterozygous, and the 
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remaining 2 patients (0.5%) were found to have two copies of the factor 5 Leiden 
mutation.  The remaining  90.7% of patients tested were found to have no evidence for 
the  factor 5 Leiden mutation.  In absolute terms, 3701 patients were found to lack the 
factor five Leiden mutation over the relevant five year period.  
 
 
2] 
These initial results prompted further subset analysis within these two groups. 
Of the 188 patients that demonstrated APC resistance, 63.3% (119 patients) were also 
tested for the factor 5 Leiden gene mutation, while the remaining 36.7% (69 patients) 
were not tested (table 3).  Of those with APC-resistance who were tested for the factor 
five Leiden mutation, 50.5% (95 patients) were confirmed to have either one or two 
copies of the factor five Leiden gene mutation.  Therefore, of those patients 
demonstrating APC resistance with factor 5 Leiden gene testing on record, 12.8% (24 
patients) were negative for the specific mutation.   
 
3] 
We next determined how many patients were tested for APC-R only (and not for 
the factor five Leiden gene mutation), how many patients were tested for both APC-R 
and the factor five Leiden gene mutation, and how many patients were tested for the 
factor five Leiden gene mutation only (and not APC-R). 
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We found that 991 patients were tested for APC-R only, 1113 patients were tested 
for both APC-R and factor five Leiden gene mutation, and 2969 patients were tested for 
the factor five Leiden gene mutation but not for APC resistance. 
 
Of those who had only been tested for APC-R, 7.0% (69 patients) demonstrated 
APC-R, indicating that this positive finding was not further investigated with a factor five 
Leiden gene mutation test.  In other words, we identified 69 patients who demonstrated 
APC resistance, but who did not have factor five Leiden mutation test results on record.  
Of those who had only been tested for the factor five Leiden gene mutation, 9.5% (283 
patients) were positive.  In other words, of the 2969 patients who were tested for the 
factor five Leiden gene mutation but not APC resistance, 90.5% of them (2686 patients) 
tested negative.  Since the factor five Leiden gene mutation test costs $83.37 as of 
November 2015, this represents $223,931 of healthcare expenditures over a five year 
period, used to determine that patients who had not undergone APC-R screening were 
negative for the factor 5 Leiden mutation.  This averages to $44,786 per year in testing 
for the factor 5 Leiden mutation in patients who have not been tested for APC-resistance. 
 
4] 
We carefully reviewed the medical charts of the patients who demonstrated APC 
resistance but tested negative for the factor five Leiden gene mutation.  Of these 24 
patients examined, by far the most common associated pathologic condition was systemic 
lupus erythematosus or antiphospholipid antibody syndrome.  Eight patients or 33% of 
non-Leiden APC resistance demonstrated specific immunologic evidence for lupus or for 
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antiphospholipid antibodies, as indicated either by a positive dilute Russell viper venom 
time, anti beta-2 glycoprotein 1 antibodies, anticardiolipin antibodies, or anti double 
stranded DNA antibodies.   
 
Two patients had undergone liver transplantation, prior to testing positive for 
APC resistance.  The first is a 23 year old female born with biliary atresia, who 
consequently received a liver transplant at age 3 in 1996.  In 2015, she was diagnosed 
with hepatic artery thrombosis, and was noted to have abnormal APC resistance of 1.83.  
However, her factor five Leiden gene mutation testing was negative.  A variety of 
hypercoagulability tests yielded negative results.  Ultimately, tissue from her liver biopsy 
was sent for the factor five Leiden gene mutation, and was found to be heterozygous.  In 
light of these findings, she was started on warfarin for a 3 month period, with plans to use 
Coumadin only post-operatively for thrombosis prophylaxis.   
 
The second patient is a 5 year old male with a history of familial 
hypercholesterolemia, who underwent liver transplantation in April of 2013.  He was 
subsequently tested for APC resistance, which was found to be abnormal, at 2.14.  A 
subsequent factor five Leiden gene mutation test was negative.  In light of these 
discordant findings, a strong possibility is that the patient was transplanted with a liver 
containing either a factor five Leiden mutation or a non-Leiden mutation in the factor five 
gene, leading to APC resistance due to mutant protein production, but negative genetic 
studies, because the patient’s leukocytes contain wild type copies of the factor five gene.   
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5]  
 
Considering the patients who demonstrated APC-resistance, we honed in further 
on the relationship between etiology and the quantitative value for APC resistance.  We 
found that patients with APC-resistance who were confirmed to be heterozygous for the 
factor five Leiden gene mutation had an average APC-R of 1.85, with a standard 
deviation of 0.14  (95 patients) (see figure 1).   
 
Of the patients with documented APC resistance but a negative factor five Leiden 
mutation test, the average APC resistance value was 1.97, with a standard deviation of 
0.29 (24 patients) (Figure 2).  Using unpaired (student’s) T Tests, P values were 
calculated to compare the populations of patients with 0 and 1 copy (heterozygotes) of 
the factor five Leiden gene mutation.  The P value was 0.0023.  
 
Of the patients who had APC resistance, but no testing on record for the factor 
five Leiden gene mutation, the average value for APC-resistance was 1.87 (69 patients), 
with a standard deviation of 0.14.   
  
6] 
We were not only interested in identifying those patients with positive APC-
resistance testing but a negative factor five Leiden test, but also in those patients with the 
converse.  Therefore, we queried our dataset for patients that tested positive for the factor 
5 Leiden gene mutation, but negative for APC resistance.  In the 5 years we studied, three 
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such patients were found.  One of these patients was a 30 year old female with a history 
of celiac disease, factor 5 Leiden heterozygosity, and subsequently presented with 
cirrhosis of unclear etiology, but likely due to a combination of Budd-Chiari syndrome 
and autoimmune hepatitis (negative ANA, anti F-actin IgA 66.1, anti-liver-kidney 
microsomal Ig 2.8, Total IgG 1426).  She received a liver transplant in early May, 2012, 
and unfortunately her postoperative course was complicated by an apparent left posterior 
cerebral artery infarction (which was subsequently found to be a fungal brain abscess).  A 
hypercoagulable panel was sent as part of a neurologic workup, which indicated APC-
resistance of 3.5.  As such the lab medicine physician entered the following interpretation 
into the chart.  “No deficiency in natural anticoagulants (protein C, protein S and 
antithrombin).  No evidence for APC resistance or lupus anticoagulant.”   
 
Blood collected on the same day was sent for the factor five Leiden gene mutation 
test, which came back with the standard pathologist interpretation (figure 3).  
The most likely reason for this testing discrepancy is as follows.  The patient was born 
with one copy of the factor five gene containing the Leiden mutation, and one wild type 
factor five gene.  Thus every cell in her body contained one wild type copy of factor five 
and one copy with the Leiden mutation.  The liver allograft she received came from a 
patient with two wild type copies of the factor five gene, which following transplantation, 
proceeded to synthesize completely wild type factor five.  As long as 3-4 half-lives of 
factor five were allowed to elapse (the plasma half-life of factor five is between 12 and 
36 hours), then the vast majority of the factor five protein in her plasma would have been 
wild type factor five, fully sensitive to cleavage by activated protein C.  This was indeed 
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the case, as the stroke she sustained, as well as the subsequent thrombophilia workup 
both occurred over 1 week after the transplant was completed.   
 
Since the factor five circulating in her blood stream would have been wild type by 
that point, it is not surprising that her APC resistance testing returned negative.  Her 
factor five Leiden testing remained heterozygous, simply because the tissue obtained for 
the mutation analysis was the peripheral leukocytes, which were generated from her bone 
marrow which was genetically her own, and as such these cells continued to carry one 
copy of the factor five Leiden mutation, which is now of no physiologic consequence.  In 
short, following transplantation with a liver allograft, the patient became a chimera – with 
the allogeneic liver generating wild type factor five protein causing normal APC 
resistance testing, and her peripheral leukocytes faithfully carrying one copy of the 
Leiden mutation, which continued to be detected by the molecular assay.  Of note, this 
patients germ cells also continue to carry the factor five Leiden mutation.  Therefore, 
although the patient herself has been alleviated of her hypercoagulable state by the liver 
transplant, her children are still at a 50% risk of inheriting one copy of the factor 5 Leiden 
mutation from their mother. 
 
Interestingly, at her most recent follow up appointment, the liver transplant 
specialist noted that “due to issues with thrombosis, she is not a good candidate for oral 
contraceptives,” seemingly due to the consistent mentioning of her heterozygosity for the 
factor five Leiden gene mutation throughout her medical chart, despite her successful 
liver transplant and subsequent normalization of her APC resistance testing. 
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The second patient who had a positive factor five Leiden gene mutation test but 
negative APC-resistance is a 35 year old female with no personal history of thrombosis 
but diagnosed with compound heterozygosity for the MTHFR C677T and A1298C 
mutations (with normal homocysteine levels).  As part of further coagulation workup, she 
was determined to be heterozygous for the factor five Leiden gene mutation.  
Unfortunately, her written electronic medical record does not extend back to this time 
period, but the coagulation diagnostics are quite informative.  She had a history of being 
treated with post-partum lovenox due to the aforementioned genetic findings, and within 
one week of her positive APC resistance testing, had a PTT of 31.3 seconds (PT/INR 
11.4 seconds/1.00).  Thus, it is quite possible that at baseline, this patient would 
demonstrate APC resistance.  However, due to anticoagulation, her elevated baseline PTT 
may very well explain the negative APC resistance testing, and its discordance with the 
positive genetic test for the factor five Leiden gene mutation. 
 
The third and final patient is a 54 year old male who suffered his second 
myocardial infarction in 2010. He subsequently had a coronary artery bypass graft, and 
he was diagnosed post-operatively with a massive left thigh deep vein thrombosis as well 
as with bilateral pulmonary emboli.  He was subsequently diagnosed with heterozygosity 
for the factor five Leiden gene mutation and noted to have an APC resistance of 2.35 
(which was regarded as unremarkable) in the immediate post-operative period during a 
thrombophilia workup.  Although unfortunately, the written electronic medical record 
does not extend back to this time period, it is clearly stated in subsequent documentation 
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that he received heparin in the Hospital as treatment for the aforementioned thrombo-
emboli, which very likely explains his normal APC resistance testing despite a positive 
genetic assay for the factor five Leiden gene mutation. 
 
In summary, three patients over the past five years exhibited negative APC 
resistance despite a positive factor five Leiden gene mutation test.  Two of these patients 
were likely actively receiving anticoagulation during the testing, and the third had 
previously received a liver transplant, indicating that far greater than 99% of patients with 
at least one germline copy of the factor five Leiden gene will be detected by APC 
resistance testing.   
 
7]  
 We also sought to determine the diagnostic routes that are typically used to arrive 
at a diagnosis of the factor five Leiden gene mutation.  Of the 4082 patients tested for the 
factor five Leiden gene mutation over the past five years, 381 were positive for at least 
one copy of the mutation.  Strikingly, of the 381 total patients testing positive for the 
factor five Leiden gene mutation, only 98 of them, or 25.7% had been tested for APC 
resistance by the coagulation lab at Yale New Haven Hospital over the same time period 
table 4).  Therefore, 283 or 74.3% of the 381patients with factor five Leiden mutations 
did not have APC resistance testing on record over the five year time period mentioned.   
 
 Of the 1113 patients who were tested for both APC resistance and the factor five 
Leiden gene mutation, 8.8%, or 98 patients tested positive for the factor five Leiden gene 
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mutation.  Finally, of the 119 patients who demonstrated APC resistance and also had 
factor five Leiden testing on record, 79.8% (95 patients) were confirmed to have the 
factor five Leiden gene mutation. 
 
DISCUSSION 
 
In the current study, we sought to examine thrombophilia testing at Yale New 
Haven Hospital over the past five years.  Specifically we focused on the diagnostic 
process for the most common inherited thrombophilia, the factor five Leiden gene 
mutation, for which two primary lab tests are available: APC-resistance, a phenotypic test 
that measures the ability of APC, an endogenous anticoagulant to prolong the PTT of a 
patient’s plasma in vitro, and the factor five Leiden molecular test, a genotypic assay that 
simply probes for the single nucleotide change from the DNA of a patient’s leukocytes 
that ultimately makes the factor five protein impervious to cleavage by APC.  Since it is 
sensitive and inexpensive, the APC resistance assay is meant to serve as a screening test 
for the factor five Leiden mutation.  Since it is relatively expensive and highly specific, 
the factor five Leiden mutation test is designed to confirm the diagnosis in a patient 
previously flagged with a positive APC resistance. 
 
Upon analyzing our data, we noted several immediately striking trends, hinting at 
the lack of execution of the above “screen and confirm” paradigm emphasized for special 
coagulation testing at Yale-New Haven Hospital.  First, there were nearly twice as many 
factor five Leiden gene mutation tests (4220) conducted as there were APC resistance 
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assays (2201) (table 2).  Clearly, if APC resistance testing were truly used as a screening 
test for the factor five Leiden gene mutation, one would expect the lab to have conducted 
far more APC resistance assays than factor five Leiden mutation tests.  This implies that 
nearly half of patients suspected to have the factor five Leiden mutation are being 
assayed upfront with the relatively expensive molecular test, which has a relatively low 
pre-test probability.  Most likely for many of these patients, a rapid and inexpensive APC 
resistance test would have been negative, which could have saved the healthcare system a 
significant amount of money if this paradigm were applied consistently to the thousands 
of patients in question. 
 
Unsurprisingly, we found that the vast majority (90.8%) of all factor five Leiden 
gene mutation tests over the past five years were negative, representing a significant 
opportunity for reducing healthcare costs if a large number of these patients would have 
simply been tested for APC resistance beforehand, thereby obviating the additional and 
unnecessary cost of the molecular assay.  In light of the sensitivity of APC-R testing for 
identifying factor five Leiden mutations demonstrated by our study, this would be a much 
more cost-effective approach.   
 
We reasoned that perhaps patients who were tested directly for the factor five 
Leiden mutation without prior APC resistance testing were treated as such due to a higher 
pre-test probability.  For example, perhaps this group was comprised of patients with a 
notable family history of confirmed factor five Leiden mutations.  However, we noted 
that the patients who had only had factor five ledien testing on record without APC 
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resistance testing, had a nearly identical rate of positivity for the mutation.  Specifically, 
we found that 90.5% of these 2969 mono-tested patients were found to have no evidence 
for the factor five Leiden gene mutation.  Thus, it was readily apparent from our initial 
analysis, that the factor five Leiden gene mutation test has been over-utilized over the 
past five years at Yale-New Haven Hospital.   
 
 After observing the over-abundance of factor five Leiden gene mutation tests, we 
also wondered if in certain situations, the test was being order sufficiently.  Specifically, 
we wanted to know if all patients with positive APC resistance testing were followed up 
with molecular testing for the factor five Leiden gene mutation test.   We found that 
36.7% of APC resistant patients had no factor five Leiden testing on record.  Of course, 
this could be due to gaps in the electronic medical record.  For example, in a patient’s 
provider pursued external testing with an outside lab that wasn’t entered into the patients’ 
electronic medical record.  We also considered the possibility that clinicians were less 
likely to pursue molecular testing if the patient’s APC resistance was less dramatic, as the 
assay is quantitative.  However, we noted that patients without molecular testing on 
record had indistinguishable APC resistance values from those confirmed to be 
heterozygous for the factor five Leiden mutation.  Specifically, the 69 patients with 
positive APC resistance but no factor five Leiden testing on record, the average APC 
resistance was 1.86 (figure 4).  The 95 patients with positive APC resistance who were 
found to be heterozygous for the factor five Leiden mutation had an average APC 
resistance value of 1.85.    
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 It is well known that patients with factor five Leiden mutations are not the only 
patients expected to test positive for APC resistance.  Among our patient population, we 
found that the most common association with non-Leiden APC resistance was serologic 
evidence for the lupus anticoagulant or the anti-phospholipid antibody syndrome.  We 
also noted a previously unheralded risk factor for acquired APC resistance – liver 
transplantation.  We described two cases of patients with abnormal APC resistance 
testing which was proceeded by a liver transplant.  Since factor five is produced by the 
hepatocytes, these patients’ circulating factor five is derived from the donor liver, whose 
genotype is not their own.  In short, these patients are genotypic chimeras, with their own 
bone marrow, and the liver of another.   
 
 We were also interested in discordance in the opposite direction – in other words 
patients with positive factor five Leiden genetic testing, but negative APC resistance.  
Overall, we found this to be a far rarer occurrence – only three patients were identified 
over a five year period.  This reinforces the notion that APC resistance is quite sensitive 
as a screening test for the factor five Leiden mutation; of 1113 patients tested for both 
factor five Leiden and APC resistance, only three of them had positive factor five Leiden 
mutation and negative APC resistance – and all three had plausible explanations.  Chart 
review indicated that one of them was actively receiving intravenous heparin, and the 
other was receiving enoxaparin and had an elevated PTT around the time of APC 
resistance testing.    In addition, we once again found that liver transplantation was an 
important differential to consider when considering discordance between APC resistance 
and factor five Leiden testing, as indicated by a patient who seems to have been 
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alleviated of her APC resistance by a liver transplant, despite consistently testing positive 
for the factor five Leiden gene mutation, when her peripheral leukocytes were accurately 
reported to contain the factor five Leiden gene mutation.  
 Finally, seeking to uncover a clear genotype-phenotype correlation, we calculated 
the average APC resistance value for patients depending on their factor five Leiden 
genotype.  Heterozygotes were typically clustered around APC resistance values of 1.85, 
whereas patients with a negative factor five Leiden assay had an average APC resistance 
of 1.97.  Therefore, examination of this data revealed an important trend that we can use 
as a predictor of factor five Leiden status based on APC resistance alone.  No APC 
resistant patient ultimately found to have a factor five Leiden mutation had an APC 
resistance value greater than 2.16 (a total of 95 patients over the past five years).  Further, 
84% of these Leiden positive patients demonstrated APC resistance values of 2.00 or 
lower.   
  
 On the other hand, of the 24 patients with positive APC resistance but a negative 
factor five Leiden test, 16 of them (67%) had APC resistance values of 2.01 or greater. 
Therefore, we can expect that in the vast majority of cases those patients with APC 
resistance of 2.01 or higher are much more likely to test negative for the factor five 
Leiden gene mutation.  On the other hand, patients with APC resistance values of 2.00 or 
lower, are far more likely to ultimately test positive for the factor five Leiden mutation.   
 
CONCLUSIONS 
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In the present study, our findings suggest several opportunities for improvement 
in the diagnosis and management of patients suspected to have a hypercoagulable state.  
Due to the overabundance of factor five Leiden gene mutation tests conducted in the 
absence of prior APC resistance testing, (and in light of the extremely high sensitivity of 
APC resistance testing for the factor five Leiden mutation) it would seem to be a 
reasonable lab policy to require documented APC-R testing before accepting specimens 
for factor five Leiden testing.  If the APC resistance is negative, then an appropriate 
interpretation could be sent back to the clinician indicating that the factor five Leiden 
gene mutation has been effectively ruled out by negative APC resistance testing.  If the 
APC resistance is positive, but above 2.01, an intermediate sign-out could be offered, 
suggesting that “low level” APC resistance is present, and hence the factor five Leiden 
mutation is possible, but less likely.  Specifically, if the APC resistance is between 2.01 
and 2.19, there is approximately a 51.6 % chance the patient will test negative for the 
factor five Leiden mutation, and a 48.3% chance the test will reveal a factor five Leiden 
mutation.  Further workup for antiphospholipid antibodies, lupus anticoagulant, and other 
associated immunologic markers for SLE, like ANA or anti dsDNA antibodies could also 
be recommended.  
 
On the other hand, if the APC resistance value is 2.00 or lower, there is a 90.9% 
chance that the factor five Leiden test will be positive, and only a 9.1% chance the patient 
will test negative for a factor five Leiden mutation. 
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 As a result, APC resistance values 2.00 or below should automatically reflex to 
the factor five Leiden gene mutation test.  This adjusted paradigm would undoubtedly 
accomplish two major goals.  First, it would reduce the overall cost associated with APC 
resistance and factor five Leiden gene mutation testing, by massively reducing the 
number of factor five Leiden gene mutation tests that are negative.  If all factor five 
Leiden gene mutation tests were only conducted on APC resistant patients, we can 
reasonably expect approximately 79% of them to be positive.  This would likely lead to 
higher clinician satisfaction with the lab workup of thrombophilias, as currently over 
90% of factor five Leiden mutation tests return negative.  This would also clearly reduce 
overall healthcare costs for the Hospital system, saving tens of thousands of dollars each 
year simply by instituting a modified utilization scheme while using the same individual 
diagnostic tests. 
 
Second, we propose that when signing out factor five Leiden mutation testing into 
the electronic medical record, the pathologists should always refer to the results of the 
APC resistance testing.  This would increase clinician awareness about the utility of the 
APC resistance test, and reinforce its role at the very top of the thrombophilia workup, as 
a screening test for the factor five Leiden mutation.   
 
Finally, when entering a signout interpretation into the electronic medical record 
for patients with APC resistance testing but a negative factor five Leiden gene mutation 
test, the most common differential diagnoses for this situation should be mentioned – 
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including non-Leiden factor five mutations including factor five Cambridge, liver 
transplantation and antiphospholipid antibodies, and the lupus anticoagulant. 
 
In summary, an evaluation of the APC resistance and factor five Leiden testing at 
Yale-New Haven Hospital between 2010 and 2015 was undertaken.  An overabundance 
of factor five Leiden gene mutation testing and corresponding financial ramifications 
were considered.  It was also noted that quantitative APC resistance values are directly 
related to the factor five Leiden genotype.  Discordance between APC resistance testing 
and factor five Leiden testing was also examined, and autoimmune disease and liver 
transplantation were identified as common associations.  In light of these observations, 
specific modifications to the thrombophilia diagnostic scheme have been proposed.  
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Figure 1.  Distribution of APC-R Values for All APC-Resistant Patients found to be 
Factor 5 Leiden Heterozygotes Over a 5 year Period 
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Figure 2.  Distribution of APC-R Values for All APC-Resistant Patients found to be 
negative for the Factor 5 Leiden Mutation Over a 5 year Period 
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Figure 3.  Laboratory Medicine Signout for a Positive Factor 5 Leiden Gene Mutation 
Test 
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Figure 4.  Distribution of APC-R Values for All APC-Resistant Patients without Factor 5 
Leiden Mutation Testing on Record Over a 5 year Period 
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Table 2. Breakdown of Total Number of APC-R and Factor Five Leiden Tests Conducted 
at Yale-New Haven Hospital over a Five Year Period 
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Table 3. Breakdown of Patients with Positive APC-R Testing at Yale-New Haven 
Hospital Over a Five Year Period 
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Table 4. Breakdown of Patients with Positive Factor Five Leiden Mutation Testing at 
Yale-New Haven Hospital Over a Five Year Period 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
